Mobile

A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002717-21

A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary Objective: • To assess the efficacy, in term of PSA response rate, of multiple doses of CP 751,871 in combination with docetaxel and prednisone in patients with HRPC.

Critère d'inclusion

  • Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)

Liens